Key statistics
As of last trade Aquestive Therapeutics Inc (AQST:NMQ) traded at 4.82, -22.71% below its 52-week high of 6.23, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.15 |
---|---|
High | 5.16 |
Low | 4.73 |
Bid | 4.81 |
Offer | 4.82 |
Previous close | 5.09 |
Average volume | 1.43m |
---|---|
Shares outstanding | 91.06m |
Free float | 86.48m |
P/E (TTM) | -- |
Market cap | 463.49m USD |
EPS (TTM) | -0.3565 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 19:20 BST.
More ▼
- Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
- Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
- Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
- Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
- Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
- Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
- Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
- Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
- Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
More ▼